Artiva Biotherapeutics, Inc./$ARTV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Ticker
$ARTV
Sector
Primary listing
Employees
106
Headquarters
Website
ARTV Metrics
BasicAdvanced
$477m
-
-$3.55
-
-
Price and volume
Market cap
$477m
52-week high
$14.53
52-week low
$1.47
Average daily volume
792k
Financial strength
Current ratio
8.156
Quick ratio
8.031
Long term debt to equity
8.228
Total debt to equity
11.683
Profitability
EBITDA (TTM)
-89.434
Management effectiveness
Return on assets (TTM)
-38.72%
Return on equity (TTM)
-67.86%
Valuation
Price to book
2.76
Price to tangible book (TTM)
2.76
Price to free cash flow (TTM)
-3.004
Free cash flow yield (TTM)
-33.29%
Free cash flow per share (TTM)
-3.269
Growth
Earnings per share change (TTM)
-15.16%
3-year earnings per share growth (CAGR)
-64.82%
ARTV News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs